Takano Toru
Department of Laboratory Medicine, Osaka University Graduate School of Medicine, Suita 565-0871, Japan.
Rinsho Byori. 2012 Feb;60(2):132-8.
Cancer is believed to be generated from normal cells via multi-step carcinogenesis. This hypothesis led researchers to perform studies utilizing genetic alternations in cancer cells in pre or post operative diagnostic tests. However, such an approach has not led to the establishment of widely used molecular-based diagnostic methods, which shows a clear contrast to conventional tumor markers. Although fine needle aspiration biopsy (FNAB) is the most accurate tool for preoperative diagnosis of thyroid malignancy, differential diagnosis between thyroid follicular adenomas and follicular carcinomas is quite difficult. Thus, a preoperative diagnostic method for follicular tumor has been anticipated for a long time. We tried to find a molecular marker to distinguish benign and malignant thyroid nodules based on a gene expression which can be used in Aspiration Biopsy-Nucleic Acid Diagnosis (ABND), and found that the decreased expression of trefoil factor 3 (TFF3) mRNA is a promising marker of thyroid malignancies, including follicular carcinoma. Furthermore, we established a novel method to separate thyroid tumor cells from blood cells using mesh filtration in order to avoid interference with peripheral blood cells that are aspirated simultaneously by FNAB. Using this method, we started a clinical trial and measured TFF3 mRNA in aspirates obtained from patients with a thyroid nodule. All preoperative aspirates diagnosed as malignant by cytology showed a low TFF3 mRNA expression. The preoperative aspirates diagnosed as benign by cytology showed extremely varied TFF3 mRNA expressions and about 20% showed a low TFF3 mRNA expression. Since ABND measuring TFF3 mRNA in aspirates covers the majority of thyroid malignancies and thyroid nodule is a very common clinical problem, it is expected to be the first widely used molecular-based screening test of cancer.
癌症被认为是通过多步骤致癌过程从正常细胞产生的。这一假说促使研究人员在术前或术后诊断测试中利用癌细胞中的基因改变进行研究。然而,这种方法尚未导致建立广泛使用的基于分子的诊断方法,这与传统肿瘤标志物形成了鲜明对比。尽管细针穿刺活检(FNAB)是术前诊断甲状腺恶性肿瘤最准确的工具,但甲状腺滤泡性腺瘤和滤泡癌之间的鉴别诊断相当困难。因此,长期以来人们一直期待有一种针对滤泡性肿瘤的术前诊断方法。我们试图基于一种可用于穿刺活检 - 核酸诊断(ABND)的基因表达来寻找一种区分甲状腺良恶性结节的分子标志物,发现三叶因子3(TFF3)mRNA表达降低是包括滤泡癌在内的甲状腺恶性肿瘤的一个有前景的标志物。此外,我们建立了一种利用网格过滤从血细胞中分离甲状腺肿瘤细胞的新方法,以避免 FNAB 同时抽吸的外周血细胞的干扰。使用这种方法,我们启动了一项临床试验,并测量了从甲状腺结节患者获取的穿刺物中的 TFF3 mRNA。所有经细胞学诊断为恶性的术前穿刺物均显示 TFF3 mRNA 低表达。经细胞学诊断为良性的术前穿刺物显示 TFF3 mRNA 表达差异极大,约 20%显示 TFF3 mRNA 低表达。由于在穿刺物中测量 TFF3 mRNA 的 ABND 涵盖了大多数甲状腺恶性肿瘤,且甲状腺结节是一个非常常见的临床问题,因此有望成为首个广泛使用的基于分子的癌症筛查测试。